Sequence analysis of the spike protein gene of murine coronavirus variants: study of genetic sites affecting neuropathogenicity.
Identifieur interne : 003554 ( PubMed/Corpus ); précédent : 003553; suivant : 003555Sequence analysis of the spike protein gene of murine coronavirus variants: study of genetic sites affecting neuropathogenicity.
Auteurs : F I Wang ; J O Fleming ; M M LaiSource :
- Virology [ 0042-6822 ] ; 1992.
English descriptors
- KwdEn :
- Animals, Antibodies, Monoclonal (immunology), Base Sequence, Central Nervous System Diseases (microbiology), Cloning, Molecular, Coronaviridae (genetics), Coronaviridae (pathogenicity), Coronaviridae Infections (microbiology), Genetic Variation, Membrane Glycoproteins, Mice, Neutralization Tests, Spike Glycoprotein, Coronavirus, Tumor Cells, Cultured, Viral Envelope Proteins (genetics), Viral Envelope Proteins (immunology).
- MESH :
- chemical , genetics : Viral Envelope Proteins.
- chemical , immunology : Antibodies, Monoclonal, Viral Envelope Proteins.
- genetics : Coronaviridae.
- microbiology : Central Nervous System Diseases, Coronaviridae Infections.
- pathogenicity : Coronaviridae.
- Animals, Base Sequence, Cloning, Molecular, Genetic Variation, Membrane Glycoproteins, Mice, Neutralization Tests, Spike Glycoprotein, Coronavirus, Tumor Cells, Cultured.
Abstract
Mouse hepatitis virus (MHV), a coronavirus, causes encephalitis and demyelination in susceptible rodents. Previous investigations have shown that the MHV spike (S) protein is a critical determinant of viral tropism and pathogenicity in mice and rats. To understand the molecular basis of MHV neuropathogenesis, we studied the spike protein gene sequences of several neutralization-resistant variants of the JHM strain of MHV, which were selected with monoclonal antibodies (MAbs) specific for the S protein. We found that variant 2.2-V-1, which was selected with MAb J.2.2 and primarily caused demyelination, had a single point mutation at nucleotide (NT) 3340, as compared to the parental JHM virus, which predominantly caused encephalitis. This site was in the S2 subunit of the S protein. In contrast, variant 7.2-V-1, which was selected with MAb J.7.2 and primarily caused encephalitis, had two point mutations at NT 1766 and 1950, which were in the S1 subunit. Finally, the double mutant 2.2/7.2-V-2, which was selected with both MAbs J.2.2 and J.7.2, and was attenuated with respect to both virulence and the ability to cause demyelination, had a deletion spanning from NT 1523 to 1624 in the S1 and a point mutation at NT 3340 in the S2. We conclude that at least two regions of the S protein contribute to neuropathogenicity of MHV. We have also isolated a partial revertant of 2.2-V-1, which was partially resistant to MAb J.2.2 but retained the same neuropathogenicity as the variant 2.2-V-1. This revertant retained the mutation at NT 3340, but had a second-site mutation at NT 1994, further confirming that NT 3340 contributed to the pathogenic phenotype of MHV. By comparing these results with MHV variants isolated in other laboratories, which had mutations in other sites on the S gene and yet retained the demyelinating ability, we suggest that the ability of JHM viruses to induce demyelination is determined by the interaction of multiple sites on the S gene, rather than the characteristics of a single, unique site. Our study also revealed the possible presence of microheterogeneity of S gene sequence, particularly in the S1 region, in these viruses. The sequence microheterogeneity may also contribute to the differences in their biological properties.
DOI: 10.1016/0042-6822(92)90041-m
PubMed: 1310195
Links to Exploration step
pubmed:1310195Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Sequence analysis of the spike protein gene of murine coronavirus variants: study of genetic sites affecting neuropathogenicity.</title>
<author><name sortKey="Wang, F I" sort="Wang, F I" uniqKey="Wang F" first="F I" last="Wang">F I Wang</name>
<affiliation><nlm:affiliation>Department of Neurology, School of Medicine, University of Southern California, Los Angeles 90033.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Fleming, J O" sort="Fleming, J O" uniqKey="Fleming J" first="J O" last="Fleming">J O Fleming</name>
</author>
<author><name sortKey="Lai, M M" sort="Lai, M M" uniqKey="Lai M" first="M M" last="Lai">M M Lai</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="1992">1992</date>
<idno type="RBID">pubmed:1310195</idno>
<idno type="pmid">1310195</idno>
<idno type="doi">10.1016/0042-6822(92)90041-m</idno>
<idno type="wicri:Area/PubMed/Corpus">003554</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">003554</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Sequence analysis of the spike protein gene of murine coronavirus variants: study of genetic sites affecting neuropathogenicity.</title>
<author><name sortKey="Wang, F I" sort="Wang, F I" uniqKey="Wang F" first="F I" last="Wang">F I Wang</name>
<affiliation><nlm:affiliation>Department of Neurology, School of Medicine, University of Southern California, Los Angeles 90033.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Fleming, J O" sort="Fleming, J O" uniqKey="Fleming J" first="J O" last="Fleming">J O Fleming</name>
</author>
<author><name sortKey="Lai, M M" sort="Lai, M M" uniqKey="Lai M" first="M M" last="Lai">M M Lai</name>
</author>
</analytic>
<series><title level="j">Virology</title>
<idno type="ISSN">0042-6822</idno>
<imprint><date when="1992" type="published">1992</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term>
<term>Antibodies, Monoclonal (immunology)</term>
<term>Base Sequence</term>
<term>Central Nervous System Diseases (microbiology)</term>
<term>Cloning, Molecular</term>
<term>Coronaviridae (genetics)</term>
<term>Coronaviridae (pathogenicity)</term>
<term>Coronaviridae Infections (microbiology)</term>
<term>Genetic Variation</term>
<term>Membrane Glycoproteins</term>
<term>Mice</term>
<term>Neutralization Tests</term>
<term>Spike Glycoprotein, Coronavirus</term>
<term>Tumor Cells, Cultured</term>
<term>Viral Envelope Proteins (genetics)</term>
<term>Viral Envelope Proteins (immunology)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en"><term>Viral Envelope Proteins</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Antibodies, Monoclonal</term>
<term>Viral Envelope Proteins</term>
</keywords>
<keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>Coronaviridae</term>
</keywords>
<keywords scheme="MESH" qualifier="microbiology" xml:lang="en"><term>Central Nervous System Diseases</term>
<term>Coronaviridae Infections</term>
</keywords>
<keywords scheme="MESH" qualifier="pathogenicity" xml:lang="en"><term>Coronaviridae</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Animals</term>
<term>Base Sequence</term>
<term>Cloning, Molecular</term>
<term>Genetic Variation</term>
<term>Membrane Glycoproteins</term>
<term>Mice</term>
<term>Neutralization Tests</term>
<term>Spike Glycoprotein, Coronavirus</term>
<term>Tumor Cells, Cultured</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Mouse hepatitis virus (MHV), a coronavirus, causes encephalitis and demyelination in susceptible rodents. Previous investigations have shown that the MHV spike (S) protein is a critical determinant of viral tropism and pathogenicity in mice and rats. To understand the molecular basis of MHV neuropathogenesis, we studied the spike protein gene sequences of several neutralization-resistant variants of the JHM strain of MHV, which were selected with monoclonal antibodies (MAbs) specific for the S protein. We found that variant 2.2-V-1, which was selected with MAb J.2.2 and primarily caused demyelination, had a single point mutation at nucleotide (NT) 3340, as compared to the parental JHM virus, which predominantly caused encephalitis. This site was in the S2 subunit of the S protein. In contrast, variant 7.2-V-1, which was selected with MAb J.7.2 and primarily caused encephalitis, had two point mutations at NT 1766 and 1950, which were in the S1 subunit. Finally, the double mutant 2.2/7.2-V-2, which was selected with both MAbs J.2.2 and J.7.2, and was attenuated with respect to both virulence and the ability to cause demyelination, had a deletion spanning from NT 1523 to 1624 in the S1 and a point mutation at NT 3340 in the S2. We conclude that at least two regions of the S protein contribute to neuropathogenicity of MHV. We have also isolated a partial revertant of 2.2-V-1, which was partially resistant to MAb J.2.2 but retained the same neuropathogenicity as the variant 2.2-V-1. This revertant retained the mutation at NT 3340, but had a second-site mutation at NT 1994, further confirming that NT 3340 contributed to the pathogenic phenotype of MHV. By comparing these results with MHV variants isolated in other laboratories, which had mutations in other sites on the S gene and yet retained the demyelinating ability, we suggest that the ability of JHM viruses to induce demyelination is determined by the interaction of multiple sites on the S gene, rather than the characteristics of a single, unique site. Our study also revealed the possible presence of microheterogeneity of S gene sequence, particularly in the S1 region, in these viruses. The sequence microheterogeneity may also contribute to the differences in their biological properties.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">1310195</PMID>
<DateCompleted><Year>1992</Year>
<Month>02</Month>
<Day>26</Day>
</DateCompleted>
<DateRevised><Year>2020</Year>
<Month>04</Month>
<Day>15</Day>
</DateRevised>
<Article PubModel="Print"><Journal><ISSN IssnType="Print">0042-6822</ISSN>
<JournalIssue CitedMedium="Print"><Volume>186</Volume>
<Issue>2</Issue>
<PubDate><Year>1992</Year>
<Month>Feb</Month>
</PubDate>
</JournalIssue>
<Title>Virology</Title>
<ISOAbbreviation>Virology</ISOAbbreviation>
</Journal>
<ArticleTitle>Sequence analysis of the spike protein gene of murine coronavirus variants: study of genetic sites affecting neuropathogenicity.</ArticleTitle>
<Pagination><MedlinePgn>742-9</MedlinePgn>
</Pagination>
<Abstract><AbstractText>Mouse hepatitis virus (MHV), a coronavirus, causes encephalitis and demyelination in susceptible rodents. Previous investigations have shown that the MHV spike (S) protein is a critical determinant of viral tropism and pathogenicity in mice and rats. To understand the molecular basis of MHV neuropathogenesis, we studied the spike protein gene sequences of several neutralization-resistant variants of the JHM strain of MHV, which were selected with monoclonal antibodies (MAbs) specific for the S protein. We found that variant 2.2-V-1, which was selected with MAb J.2.2 and primarily caused demyelination, had a single point mutation at nucleotide (NT) 3340, as compared to the parental JHM virus, which predominantly caused encephalitis. This site was in the S2 subunit of the S protein. In contrast, variant 7.2-V-1, which was selected with MAb J.7.2 and primarily caused encephalitis, had two point mutations at NT 1766 and 1950, which were in the S1 subunit. Finally, the double mutant 2.2/7.2-V-2, which was selected with both MAbs J.2.2 and J.7.2, and was attenuated with respect to both virulence and the ability to cause demyelination, had a deletion spanning from NT 1523 to 1624 in the S1 and a point mutation at NT 3340 in the S2. We conclude that at least two regions of the S protein contribute to neuropathogenicity of MHV. We have also isolated a partial revertant of 2.2-V-1, which was partially resistant to MAb J.2.2 but retained the same neuropathogenicity as the variant 2.2-V-1. This revertant retained the mutation at NT 3340, but had a second-site mutation at NT 1994, further confirming that NT 3340 contributed to the pathogenic phenotype of MHV. By comparing these results with MHV variants isolated in other laboratories, which had mutations in other sites on the S gene and yet retained the demyelinating ability, we suggest that the ability of JHM viruses to induce demyelination is determined by the interaction of multiple sites on the S gene, rather than the characteristics of a single, unique site. Our study also revealed the possible presence of microheterogeneity of S gene sequence, particularly in the S1 region, in these viruses. The sequence microheterogeneity may also contribute to the differences in their biological properties.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wang</LastName>
<ForeName>F I</ForeName>
<Initials>FI</Initials>
<AffiliationInfo><Affiliation>Department of Neurology, School of Medicine, University of Southern California, Los Angeles 90033.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Fleming</LastName>
<ForeName>J O</ForeName>
<Initials>JO</Initials>
</Author>
<Author ValidYN="Y"><LastName>Lai</LastName>
<ForeName>M M</ForeName>
<Initials>MM</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y"><Grant><GrantID>NS1816</GrantID>
<Acronym>NS</Acronym>
<Agency>NINDS NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
<PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>Virology</MedlineTA>
<NlmUniqueID>0110674</NlmUniqueID>
<ISSNLinking>0042-6822</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000911">Antibodies, Monoclonal</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C578553">MHV surface projection glycoprotein</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D008562">Membrane Glycoproteins</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D064370">Spike Glycoprotein, Coronavirus</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014759">Viral Envelope Proteins</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C578557">spike glycoprotein, SARS-CoV</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000911" MajorTopicYN="N">Antibodies, Monoclonal</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D001483" MajorTopicYN="N">Base Sequence</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D002493" MajorTopicYN="N">Central Nervous System Diseases</DescriptorName>
<QualifierName UI="Q000382" MajorTopicYN="Y">microbiology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D003001" MajorTopicYN="N">Cloning, Molecular</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D003332" MajorTopicYN="N">Coronaviridae</DescriptorName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
<QualifierName UI="Q000472" MajorTopicYN="Y">pathogenicity</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D003333" MajorTopicYN="N">Coronaviridae Infections</DescriptorName>
<QualifierName UI="Q000382" MajorTopicYN="Y">microbiology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014644" MajorTopicYN="N">Genetic Variation</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008562" MajorTopicYN="Y">Membrane Glycoproteins</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D009500" MajorTopicYN="N">Neutralization Tests</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D064370" MajorTopicYN="N">Spike Glycoprotein, Coronavirus</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014407" MajorTopicYN="N">Tumor Cells, Cultured</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014759" MajorTopicYN="N">Viral Envelope Proteins</DescriptorName>
<QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1992</Year>
<Month>2</Month>
<Day>1</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>1992</Year>
<Month>2</Month>
<Day>1</Day>
<Hour>0</Hour>
<Minute>1</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>1992</Year>
<Month>2</Month>
<Day>1</Day>
<Hour>0</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">1310195</ArticleId>
<ArticleId IdType="doi">10.1016/0042-6822(92)90041-m</ArticleId>
<ArticleId IdType="pmc">PMC7131202</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>Virology. 1989 Jul;171(1):141-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">2545027</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Microb Pathog. 1987 Jul;3(1):9-20</Citation>
<ArticleIdList><ArticleId IdType="pubmed">2848172</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Microbiol Immunol. 1983;27(5):445-54</Citation>
<ArticleIdList><ArticleId IdType="pubmed">6312277</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Science. 1988 Jan 29;239(4839):487-91</Citation>
<ArticleIdList><ArticleId IdType="pubmed">2448875</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Gen Virol. 1988 Jan;69 ( Pt 1):87-98</Citation>
<ArticleIdList><ArticleId IdType="pubmed">2447229</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Infect Immun. 1981 Mar;31(3):1214-22</Citation>
<ArticleIdList><ArticleId IdType="pubmed">7228403</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Virol. 1985 Dec;56(3):904-11</Citation>
<ArticleIdList><ArticleId IdType="pubmed">2999443</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Virology. 1983 Dec;131(2):296-307</Citation>
<ArticleIdList><ArticleId IdType="pubmed">6318433</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Virology. 1991 Jun;182(2):883-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">1850936</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Virol. 1990 Feb;64(2):731-41</Citation>
<ArticleIdList><ArticleId IdType="pubmed">1688627</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Virology. 1981 Sep;113(2):503-11</Citation>
<ArticleIdList><ArticleId IdType="pubmed">6267795</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Virology. 1987 Dec;161(2):479-87</Citation>
<ArticleIdList><ArticleId IdType="pubmed">2825419</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Exp Med. 1981 Apr 1;153(4):832-43</Citation>
<ArticleIdList><ArticleId IdType="pubmed">6265583</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Virol. 1978 May;26(2):236-42</Citation>
<ArticleIdList><ArticleId IdType="pubmed">207885</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Virology. 1989 Jan;168(1):162-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">2535900</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Mol Biol. 1987 Aug 20;196(4):963-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">3681988</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Annu Rev Microbiol. 1990;44:303-33</Citation>
<ArticleIdList><ArticleId IdType="pubmed">2252386</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Virol. 1990 Jun;64(6):3051-5</Citation>
<ArticleIdList><ArticleId IdType="pubmed">1692350</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Arch Neurol. 1973 May;28(5):298-303</Citation>
<ArticleIdList><ArticleId IdType="pubmed">4348723</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Virol. 1986 Jun;58(3):869-75</Citation>
<ArticleIdList><ArticleId IdType="pubmed">3701929</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Gen Virol. 1982 Dec;63(2):265-75</Citation>
<ArticleIdList><ArticleId IdType="pubmed">6296277</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Virol. 1989 Mar;63(3):1408-12</Citation>
<ArticleIdList><ArticleId IdType="pubmed">2464703</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Virology. 1991 Feb;180(2):567-82</Citation>
<ArticleIdList><ArticleId IdType="pubmed">1846489</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Virology. 1982 Jun;119(2):358-71</Citation>
<ArticleIdList><ArticleId IdType="pubmed">6281979</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Virol. 1991 Jan;65(1):254-62</Citation>
<ArticleIdList><ArticleId IdType="pubmed">1985201</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Virology. 1990 Apr;175(2):548-55</Citation>
<ArticleIdList><ArticleId IdType="pubmed">2158184</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Neuroimmunol. 1990 Nov;30(1):31-41</Citation>
<ArticleIdList><ArticleId IdType="pubmed">2172304</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Gen Virol. 1987 Jan;68 ( Pt 1):47-56</Citation>
<ArticleIdList><ArticleId IdType="pubmed">3027248</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Virol. 1986 Aug;59(2):463-71</Citation>
<ArticleIdList><ArticleId IdType="pubmed">3016306</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Arch Gesamte Virusforsch. 1974;44(3):298-302</Citation>
<ArticleIdList><ArticleId IdType="pubmed">4365902</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Virology. 1989 Dec;173(2):664-73</Citation>
<ArticleIdList><ArticleId IdType="pubmed">2556846</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Virology. 1984 Jan 30;132(2):261-70</Citation>
<ArticleIdList><ArticleId IdType="pubmed">6199889</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Virol. 1991 Sep;65(9):5013-28</Citation>
<ArticleIdList><ArticleId IdType="pubmed">1651420</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Virol. 1991 Apr;65(4):1916-28</Citation>
<ArticleIdList><ArticleId IdType="pubmed">1848311</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Lab Invest. 1990 May;62(5):570-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">2160561</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Virology. 1991 Aug;183(2):647-57</Citation>
<ArticleIdList><ArticleId IdType="pubmed">1649505</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Adv Virus Res. 1983;28:35-112</Citation>
<ArticleIdList><ArticleId IdType="pubmed">6362367</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Virol. 1986 Jul;59(1):168-71</Citation>
<ArticleIdList><ArticleId IdType="pubmed">3012115</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003554 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 003554 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Sante |area= SrasV1 |flux= PubMed |étape= Corpus |type= RBID |clé= pubmed:1310195 |texte= Sequence analysis of the spike protein gene of murine coronavirus variants: study of genetic sites affecting neuropathogenicity. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:1310195" \ | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \ | NlmPubMed2Wicri -a SrasV1
![]() | This area was generated with Dilib version V0.6.33. | ![]() |